Pay in 4 interest-free payments of $7.45 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
As illustrated in Additional file 1: Figure S1C, animals from both TAT and TAT-DAT NT did not differ in time spent in each duration (two-way ANOVA with repeated measures, F 1, 10 = 0.321, p = NS), suggesting that the differences in spontaneous alternation behavior were unlikely due to confounding factors such as anxiety
First investigations are currently being performed using a mouse model with artificial induced lung infections
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Always talk to a doctor to stay safe
US$ 28.65
US$ 23.06
US$ 21.32
US$ 26.00
US$ 28.43